Ottobock stock
Price history
−48.36% over the period1 year: from €73.00 (November 20, 2025) to €37.70 (November 20, 2026), −48.36%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €37.70 |
| October 30, 2026 | €48.15 |
| September 30, 2026 | €53.10 |
| August 31, 2026 | €59.80 |
| July 31, 2026 | €56.10 |
| June 30, 2026 | €50.80 |
| May 29, 2026 | €52.80 |
| April 30, 2026 | €58.30 |
| March 31, 2026 | €51.80 |
| February 27, 2026 | €57.00 |
| January 30, 2026 | €60.75 |
| December 30, 2025 | €65.25 |
| November 28, 2025 | €73.95 |
| November 20, 2025 | €73.00 |
At a glance
The company
Develop, produce and distribute prosthetics, orthotics, mobility aids and exoskeletons for people with disabilities worldwide
Latest results
Quarter to June 30, 2026 · EPS €1.06
TickerLandia's take on Ottobock
- Cheaper than similar companies: trailing 12-month P/E 19 vs 25 (−24%) in a group of 9.
- Strong point: Growth (68/100 in its group). Weak point: Market momentum (4/100).
- “Most upside for analysts” (Germany): No. 1 of 93.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−42.00% from the 52-week high
Analysts · 8 analysts
Average target€72.25+91.64% vs. price
Buy 7 · Hold 1 · Sell 0 · Strong buy
TickerLandia Fingerprint: Ottobock
Compared with similar companies: very weak momentum and very low price.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery low19
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 19.0 5 Forward P/E 10.7 1 EV/EBITDA 9.63 7 Price/book 5.41 66 Price/sales 1.38 13 Profitabilityhigh65
How much it earns on revenue and capital.
Metric Value Position in group Net margin 8.5% 49 ROE 41.5% 99 Gross margin 53.1% 46 ROA 9.6% 69 Operating margin 18.7% 63 Earnings stabilityaverage50
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 4.0% 37 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthhigh68
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +7.98% 63 Revenue growth (year over year) +8.80% 69 Earnings growth (year over year) +82.90% 71 Financial strengthlow28
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 3.95 28 Current ratio 1.28 31 Debt/equitycounts in reverse: lower means more financial strength 2.72 2 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.91 52 Dividendaverage54
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 1 year 10 Payout ratio 48.3% 65 Dividend yield 2.5% 89 Market momentumvery weak4
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −32.83% 3 Relative strength (6 months) −31.51% 9 1-year return −48.36% 2 Distance from 200-day average −30.39% 4 Riskhigh75
How much the price swings.
Metric Value Position in group Beta (1 year) 0.70 46 Volatility (60 days) 42.6% 86 Maximum drawdown (12 months) 50.2% 94
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Ottobock is cheaper than similar companies
Ottobock's P/E (trailing 12 months): 19.0, −24% against the median of a group of 9 similar companies (25.1).
Compared with 9 similar companies
| Metric | Ottobock | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 19.0 | Low | |
| Forward P/E | 10.7 | Low | |
| Operating margin | 18.7% | High | |
| ROE | 41.5% | High | |
| Debt/equity | 2.72 | High |
Grey band: the middle half of the group; tick: the median; dot: Ottobock. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€458.1M
Latest quarter · Q2 2026
Net income
€48.8M
Latest quarter · Q2 2026
Quarterly net margin
10.7%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €2.44B
- P/E
- 19.0
- EPS
- €2.01
- Volume
- 79.27K
- Daily trading
- €3.02M
- Dividend yield
- 2.57%
- Last ex-dividend on May 20, 2026
How Ottobock is changing
All resultsRevenue grew 8.0% a year on average over the last 3 years
Operating margin rose from 5.1% to 14.1%
Shares outstanding up 1,047.0% in 3 years
Returns
Ottobock returns with dividends
€1,000 invested in Ottobock 1 year ago, on November 20, 2025, would be worth €526 today with dividends reinvested: −47.44% in total, −47.44% per year. On price alone it would be €516 (−48.36%).
| Period | Ottobock | DAX | €1,000 becomes |
|---|---|---|---|
| 1 month | −26.22% | −1.98% | €738 |
| 6 months | −31.33% | +0.26% | €687 |
| Year to date | −42.22% | +1.28% | €578 |
| 1 year | −47.44% | +6.55% | €526 |
Over the last 6 months it has done better than 5% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment
The chart in detail
Ottobock: technical analysis
Ottobock is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 50.2% below its all-time closing high (€75.70, November 25, 2025).
- Trend
- Downward
- RSI (14 sessions)
- 19
- Below 30: a strong fall in a short time
- vs 200-session average
- −30.39%
Active signals
RSI below 30: the stock has fallen a lot in a short time.
since November 12, 2026
Support and resistance
Price areas where Ottobock has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€55.00+45.89%5 touches, last on October 14, 2026
- Resistance€53.66+42.34%4 touches, last on September 15, 2026
- Resistance€49.68+31.78%5 touches, last on November 5, 2026
- Last price€37.70
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved less than the DAX.
- Beta (1 year) vs DAX
- 0.70
- Volatility (60 sessions, annualised)
- 42.6%
- Largest fall in the last year
- −50.20%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Ottobock and its competitors
Prosthetics form the core of Ottobock SE & Co. KGaA, which designs, manufactures and sells medical technology for people with disabilities. Its range runs from arm, hand and leg prostheses, including myoelectric and microprocessor-driven models, to socket components such as liners and cosmetic covers. Orthotic devices, neuro-rehabilitation stimulators, wheelchairs, seating and clinic planning services complete the offer, and the group also rents out some equipment. Its customers include patients with limb loss, vascular disease, cancer-related amputations and neurological conditions such as stroke or multiple sclerosis.
- Headquarters
- Duderstadt, Germany
- Employees
- 9,455
- Founded
- 1919
- Chief executive
- Oliver Jakobi
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| OttobockOBCK | $2.68B | 18.7% | 19.0 | −31.33% |
| Carl Zeiss MeditecAFX | $3.07B | 7.2% | 23.3 | +24.32% |
| AddLifeALIF.B | $2.11B | 8.9% | 33.5 | +17.73% |
| Bonesupport HoldingBONEX | $2.03B | 25.5% | 78.1 | +25.60% |
| Tecan GroupTECN | $3.58B | 4.9% | — | +64.44% |
| SCHOTT Pharma1SXP | $3.74B | 16.4% | 25.1 | +34.04% |
Same industry or related industries, similar size. Compare Ottobock with its competitors · Full profile